-
EP4291238
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4291238
| EP4291238 - A PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING IMMUNE RESPONSE AGAINST CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 17.11.2023 Database last updated on 06.07.2024 | |
| Former | The international publication has been made Status updated on 19.08.2022 | Most recent event Tooltip | 12.04.2024 | Change: Validation states | published on 15.05.2024 [2024/20] | 12.04.2024 | Change - extension states | published on 15.05.2024 [2024/20] | Applicant(s) | For all designated states Great Novel Therapeutics Biotech & Medicals Corporation 16F.-5, No. 508, Sec. 7, Zhongxiao E. Rd. Nangang Dist. Taipei City 115011, Taiwan / TW | [2023/51] | Inventor(s) | 01 /
CHOU, Cheng-han Taipei City 115011 / TW | 02 /
WU, Yi-hong Taipei City 115011 / TW | 03 /
CHEN, Jia-shiong Taipei City 115011 / TW | 04 /
CHAO, Ye-su Taipei City 115011 / TW | 05 /
CHEN, Chia-nan Taipei City 115011 / TW | [2023/51] | Representative(s) | Cabinet Becker et Associés 25, rue Louis le Grand 75002 Paris / FR | [2023/51] | Application number, filing date | 21925220.2 | 10.02.2021 | [2023/51] | WO2021CN76503 | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022170557 | Date: | 18.08.2022 | Language: | EN | [2022/33] | Type: | A1 Application with search report | No.: | EP4291238 | Date: | 20.12.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.08.2022 takes the place of the publication of the European patent application. | [2023/51] | Search report(s) | International search report - published on: | CN | 18.08.2022 | Classification | IPC: | A61K45/00, A61P35/00 | [2023/51] | CPC: |
A61P35/00 (EP);
A61K31/167 (EP);
A61K31/4406 (EP);
A61K31/4439 (EP);
A61K31/47 (EP);
A61K31/502 (EP);
A61K31/519 (EP)
(-)
| C-Set: |
A61K31/167, A61K2300/00 (EP);
A61K31/4406, A61K2300/00 (EP);
A61K31/4439, A61K2300/00 (EP);
A61K31/47, A61K2300/00 (EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/51] | Title | German: | PHARMAZEUTISCHE KOMBINATION UND VERFAHREN ZUR ÜBERWINDUNG DER IMMUNSUPPRESSION ODER STIMULATION DER IMMUNREAKTION GEGEN KREBS | [2023/51] | English: | A PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING IMMUNE RESPONSE AGAINST CANCER | [2023/51] | French: | COMBINAISON PHARMACEUTIQUE ET MÉTHODE POUR SURMONTER LA SUPPRESSION IMMUNITAIRE OU STIMULER UNE RÉPONSE IMMUNITAIRE CONTRE LE CANCER | [2023/51] | Entry into regional phase | 07.08.2023 | National basic fee paid | 07.08.2023 | Search fee paid | 07.08.2023 | Designation fee(s) paid | 07.08.2023 | Examination fee paid | Examination procedure | 07.08.2023 | Amendment by applicant (claims and/or description) | 07.08.2023 | Examination requested [2023/51] | Fees paid | Renewal fee | 08.08.2023 | Renewal fee patent year 03 | 12.02.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2016210108 (IMMUNOMEDICS INC [US]) [X] 1-20 * claims 1-2， 13-15， 19-20， 25-27， 31-35 *; | [A]WO2017160717 (MEMORIAL SLOAN KETTERING CANCER CENTER [US]) [A] 1-20* The whole document *; | [X]WO2020030591 (DA VOLTERRA [FR]) [X] 1-20 * claims 1， 10-14 *; | [X]WO2020095256 (AURIGENE DISCOVERY TECH LTD [IN]) [X] 1-20 * claims 1-5， 10-13， 43-54，description paragraph 0003 *; | [X]CN111973747 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD) [X] 1-20 * claims 1， 3， 5-6， 9， description paragraphs 0043-0045、0059-0060 *; | [X]CN112043702 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD) [X] 1-20 * claims 1， 6-7，description paragraphs 0034， 0116-0119， 0126-0127 * |